The plan would put Yellow back on the road with thousands of unionized drivers, but would force the government to wait longer for a loan repayment.

Currencies around the world have weakened against the dollar, but the rupee has held strong, as virtually everything has gone right for India.

The leadership crisis exposed Microsoft’s reliance on the AI startup, showing a need for a greater role.

The Chinese online fashion company was valued at $66 billion earlier this year.

Major U.S. stock indexes inched down as all three remain on track for their best monthly performances in more than a year.

Exxon and other companies have devised ways to squeeze more oil out of U.S. fields as some of the best ones near exhaustion, but it could be costly.

The end of zero-rate policy in Japan seems like a risk to American bonds. In fact, they may already have passed the test.

Chinese authorities are taking more forceful action to contain the growing financial troubles of one of the country’s biggest shadow lenders.

Recent data has fueled bets that cuts could come under a variety of circumstances.

TikTok is moving aggressively into e-commerce—a space where its Chinese equivalent is massively successful.

Citizens Financial is scooping up bankers from First Republic. Executives say they will copy only the good parts of the failed bank.

Some analysts see the investor balances in money-market funds as a bullish sign for stocks and bonds.

The China megabank bought its U.S. broker-dealer 13 years ago for practically nothing. It got more than it bargained for.

New research tackles the source of financial conflict and what we can do about it.

Credit-card utilization and delinquency rates are on the rise.

Insiders and investors say the bank’s board, headed by Urs Rohner, was ultimately responsible for its fate.

The Dow rose more than 100 points in an abbreviated holiday session.

Binance’s landmark settlement with U.S. officials may clear the way for better exchange-traded funds based on the largest digital currency.

Several previously beaten-down sectors have been among the rally’s biggest gainers.

The first treatment based on the Nobel Prize-winning Crispr technology is poised to win FDA approval next month, offering hope to patients and opportunities to investors.